Developer docs
API playgroundTry for free, no card

Search company profiles

Ennovabio

Full company profile

uuid0002865

Namestring
Ennovabio
Legal namestring
上海轶诺药业有限公司
Websiteurl
ennovabio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Ennovabio (轶诺药业, formally Shanghai Ennovabio Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company headquartered in Shanghai's Pudong New Area, founded in 2018 by Dr. Jiang Lei (CEO) and Dr. Shou Jianyong (CSO), with additional senior leadership including Dr. Shang Ke (Biology VP), Dr. Zhang Jianhua (BD Head), Dr. Li Qian (Senior Analytics Director), and part-time CMO Dr. Peng Bin appointed in October 2023. The company focuses on developing first-in-class therapeutics for autoimmune diseases, diabetic complications, chronic inflammation, and cancer, with 6 distinct projects spanning preclinical and clinical stages. Its core technology is the proprietary eSTEM Systems Biology Platform, which integrates bioinformatics, systems biology, and machine learning/deep learning to identify and prioritize novel, traditionally 'undruggable' drug targets in autoimmune, inflammatory, and metabolic diseases.

Ennovabio operates internal drug discovery capabilities spanning target assessment, medicinal chemistry, in vitro/in vivo pharmacology, CMC, DMPK, and clinical development. The company has expanded into nucleic-acid modalities via a strategic co-development partnership with Darui Biopharma (announced January 12, 2023) to develop first-in-class siRNA therapeutics for metabolic liver diseases (NAFLD, NASH, fibrosis) using Darui's RAZOR platform alongside Ennovabio's target assessment capabilities. As of October 2025, the company was recognized as one of six winners in Bayer China's inaugural 'Co-Create New Drugs' competition for excellence in autoimmune, chronic inflammation, and metabolic complications research.

The company's revenue model is pre-commercial and based on future drug development and commercialization, with current income (if any) tied to licensing or co-development rather than product sales; pricing details are not publicly disclosed. Its go-to-market motion combines enterprise-level partnership and co-development with Big Pharma and biotech partners (Bayer, Darui Biopharma) alongside innovation competitions, scientific conferences, and academic engagement to build pipeline visibility. Capital sources to date include Series 1 funding of $10M led by Highlight Capital and Zhangke Lingyi Investment (2017), a $14M Series 2 led by Matrix Partners China (2019), a Series 2 extension led by Shanghai Biomedical Industrial Equity Investment Fund (2021), and a 2025 round with participation from K&C Capital, Shanghai Kangcheng Investment Management, and Zhangke Lingyi Investment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery, clinical-stage biotechnology, systems biology platform, autoimmune disease therapeutics, siRNA drug development
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Drug Discovery & Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Clinical-stage biopharmaceutical company developing first-in-class therapeutics for autoimmune diseases, diabetic complications, and cancer. Revenue model is pre-commercial; pipeline assets are in preclinical and clinical development stages across 6 distinct projects.

ennovabio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ennovabio is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics for autoimmune diseases, diabetic complications, cancer, and metabolic liver diseases. The company uses its proprietary eSTEM Systems Biology Platform, which integrates systems biology with machine learning and deep learning, to identify and prioritize novel drug targets. Its pipeline comprises 6 distinct projects spanning preclinical and clinical development, with internal capabilities covering target assessment, medicinal chemistry, pharmacology, CMC, DMPK, and clinical development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ennovabio (轶诺药业) is a clinical-stage biopharmaceutical company focused on first-in-class drug discovery for autoimmune diseases, diabetic complications, and cancer. The company operates its proprietary eSTEM Systems Biology Platform for target identification and drug discovery, supporting a pipeline of 6 projects spanning preclinical to clinical development stages. The company also develops siRNA therapeutics for liver diseases through strategic partnerships.

Product and service1 record
1eSTEM Systems Biology Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-12
Description

Ennovabio and Darui Biopharma entered into a strategic partnership to co-develop first-in-class siRNA therapeutics for metabolic liver diseases. Ennovabio contributes target assessment capabilities and drug discovery expertise in metabolic diseases through its eSTEM platform; Darui Biopharma contributes its proprietary RAZOR™ next-generation siRNA platform for discovering siRNA lead compounds targeting liver-protective and function-improving novel targets. The partnership aims to develop treatments for 'undruggable' targets in fatty liver disease, NASH, and liver fibrosis — conditions with no effective pharmacological treatments currently available.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chinese AI-driven drug discovery company combining physics-based modeling, quantum mechanics, and ML to identify novel drug candidates; comparable in applying AI/ML to early-stage discovery and target prioritization, with a similar first-in-class discovery orientation.

TypeEmerging player
Description

US-based AI/ML-driven drug discovery company using machine learning and high-throughput biology to discover therapeutics, with focus on metabolic and neurological disease; comparable in AI-enabled target ID approach but at later stage and broader therapeutic footprint.

TypeDirect peer
Description

Chinese clinical-stage biotech focused on precision oncology and small-molecule therapeutics; comparable as a venture-backed Shanghai-based clinical-stage biotech with similar pipeline breadth and licensing/partnering orientation.

TypeEmerging player
Description

US-based AI-driven drug discovery company combining high-throughput experimental biology with machine learning across multiple therapeutic areas; comparable in using AI/ML as a platform to systematically generate first-in-class candidates.

TypeBroad incumbent
Description

Major global Chinese-origin biopharmaceutical company with a broad pipeline across oncology and immunology; comparable as a large Chinese-founded biotech with first-in-class ambitions, though at far greater scale and with multiple commercialized products.

TypeEmerging player
Description

US-based computational drug discovery platform combining physics-based simulation with ML for hit identification, lead optimization, and target evaluation; comparable in applying computational/AI methods to accelerate small-molecule discovery.

TypeBroad incumbent
Description

Leading Chinese innovation-driven biopharmaceutical company developing first-in-class biologics and small molecules across oncology, autoimmune, and metabolic disease; comparable as a Chinese clinical-stage-to-commercial biotech pursuing innovative targets in overlapping disease areas.

TypeBroad incumbent
Description

Larger Chinese biopharmaceutical company developing innovative medicines across oncology, autoimmune, and metabolic disease with multiple approved and clinical-stage assets; comparable in therapeutic-area overlap (autoimmune, metabolic) but at significantly more advanced commercialization stage.

TypeDirect peer
Description

Strategic co-development partner of Ennovabio for siRNA-based metabolic liver disease therapeutics; a Chinese clinical-stage biotech using a proprietary next-generation siRNA platform (RAZOR™) to target metabolic, renal, CNS, and ophthalmologic diseases — directly comparable modality and disease-area overlap.

TypeDirect peer
Description

Chinese clinical-stage biotech developing innovative immunotherapies for cancer and autoimmune/inflammatory diseases; comparable in Chinese clinical-stage biotech profile and similar focus on immune-mediated disease areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ennovabio

Drug Discovery & Developmentennovabio.com

What Ennovabio does

Ennovabio (轶诺药业, formally Shanghai Ennovabio Pharmaceutical Co., Ltd.) is a clinical-stage biopharmaceutical company headquartered in Shanghai's Pudong New Area, founded in 2018 by Dr. Jiang Lei (CEO) and Dr. Shou Jianyong (CSO), with additional senior leadership including Dr. Shang Ke (Biology VP), Dr. Zhang Jianhua (BD Head), Dr. Li Qian (Senior Analytics Director), and part-time CMO Dr. Peng Bin appointed in October 2023. The company focuses on developing first-in-class therapeutics for autoimmune diseases, diabetic complications, chronic inflammation, and cancer, with 6 distinct projects spanning preclinical and clinical stages. Its core technology is the proprietary eSTEM Systems Biology Platform, which integrates bioinformatics, systems biology, and machine learning/deep learning to identify and prioritize novel, traditionally 'undruggable' drug targets in autoimmune, inflammatory, and metabolic diseases.

Ennovabio operates internal drug discovery capabilities spanning target assessment, medicinal chemistry, in vitro/in vivo pharmacology, CMC, DMPK, and clinical development. The company has expanded into nucleic-acid modalities via a strategic co-development partnership with Darui Biopharma (announced January 12, 2023) to develop first-in-class siRNA therapeutics for metabolic liver diseases (NAFLD, NASH, fibrosis) using Darui's RAZOR platform alongside Ennovabio's target assessment capabilities. As of October 2025, the company was recognized as one of six winners in Bayer China's inaugural 'Co-Create New Drugs' competition for excellence in autoimmune, chronic inflammation, and metabolic complications research.

The company's revenue model is pre-commercial and based on future drug development and commercialization, with current income (if any) tied to licensing or co-development rather than product sales; pricing details are not publicly disclosed. Its go-to-market motion combines enterprise-level partnership and co-development with Big Pharma and biotech partners (Bayer, Darui Biopharma) alongside innovation competitions, scientific conferences, and academic engagement to build pipeline visibility. Capital sources to date include Series 1 funding of $10M led by Highlight Capital and Zhangke Lingyi Investment (2017), a $14M Series 2 led by Matrix Partners China (2019), a Series 2 extension led by Shanghai Biomedical Industrial Equity Investment Fund (2021), and a 2025 round with participation from K&C Capital, Shanghai Kangcheng Investment Management, and Zhangke Lingyi Investment.

Ennovabio firmographics

Firmographics
Name
Ennovabio
Legal name
上海轶诺药业有限公司
Website
https://ennovabio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Ennovabio industry classification

Industry
Product category
Drug Discovery & Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Drug discovery
  • Clinical-stage biotechnology
  • Systems biology platform
  • Autoimmune disease therapeutics
  • SiRNA drug development

Where Ennovabio is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Ennovabio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Clinical-stage biopharmaceutical company developing first-in-class therapeutics for autoimmune diseases, diabetic complications, and cancer. Revenue model is pre-commercial; pipeline assets are in preclinical and clinical development stages across 6 distinct projects.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ennovabio product offering

Product offering

Core offering

Ennovabio is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics for autoimmune diseases, diabetic complications, cancer, and metabolic liver diseases. The company uses its proprietary eSTEM Systems Biology Platform, which integrates systems biology with machine learning and deep learning, to identify and prioritize novel drug targets. Its pipeline comprises 6 distinct projects spanning preclinical and clinical development, with internal capabilities covering target assessment, medicinal chemistry, pharmacology, CMC, DMPK, and clinical development.

Product overview

Ennovabio (轶诺药业) is a clinical-stage biopharmaceutical company focused on first-in-class drug discovery for autoimmune diseases, diabetic complications, and cancer. The company operates its proprietary eSTEM Systems Biology Platform for target identification and drug discovery, supporting a pipeline of 6 projects spanning preclinical to clinical development stages. The company also develops siRNA therapeutics for liver diseases through strategic partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

  • eSTEM Systems Biology Platform

Companies that use Ennovabio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Ennovabio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ennovabio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Darui Biopharma (大睿生物医药科技有限公司)coreStrategic or Co-development Partner · 12 January 2023Ennovabio and Darui Biopharma entered into a strategic partnership to co-develop first-in-class siRNA therapeutics for metabolic liver diseases. Ennovabio contributes target assessment capabilities and drug discovery expertise in metabolic diseases through its eSTEM platform; Darui Biopharma contributes its proprietary RAZOR™ next-generation siRNA platform for discovering siRNA lead compounds targeting liver-protective and function-improving novel targets. The partnership aims to develop treatments for 'undruggable' targets in fatty liver disease, NASH, and liver fibrosis — conditions with no effective pharmacological treatments currently available.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Ennovabio competitors and assessment

Company assessment

Direct peers

  • XtalPi: Chinese AI-driven drug discovery company combining physics-based modeling, quantum mechanics, and ML to identify novel drug candidates; comparable in applying AI/ML to early-stage discovery and target prioritization, with a similar first-in-class discovery orientation.
  • Abbisko Therapeutics: Chinese clinical-stage biotech focused on precision oncology and small-molecule therapeutics; comparable as a venture-backed Shanghai-based clinical-stage biotech with similar pipeline breadth and licensing/partnering orientation.
  • Rona Therapeutics (Darui Biopharma): Strategic co-development partner of Ennovabio for siRNA-based metabolic liver disease therapeutics; a Chinese clinical-stage biotech using a proprietary next-generation siRNA platform (RAZOR™) to target metabolic, renal, CNS, and ophthalmologic diseases — directly comparable modality and disease-area overlap.
  • Elpiscience Biopharmaceuticals: Chinese clinical-stage biotech developing innovative immunotherapies for cancer and autoimmune/inflammatory diseases; comparable in Chinese clinical-stage biotech profile and similar focus on immune-mediated disease areas.

Emerging players

  • Insitro: US-based AI/ML-driven drug discovery company using machine learning and high-throughput biology to discover therapeutics, with focus on metabolic and neurological disease; comparable in AI-enabled target ID approach but at later stage and broader therapeutic footprint.
  • Recursion Pharmaceuticals: US-based AI-driven drug discovery company combining high-throughput experimental biology with machine learning across multiple therapeutic areas; comparable in using AI/ML as a platform to systematically generate first-in-class candidates.
  • Schrödinger: US-based computational drug discovery platform combining physics-based simulation with ML for hit identification, lead optimization, and target evaluation; comparable in applying computational/AI methods to accelerate small-molecule discovery.

Broad incumbents

  • BeiGene: Major global Chinese-origin biopharmaceutical company with a broad pipeline across oncology and immunology; comparable as a large Chinese-founded biotech with first-in-class ambitions, though at far greater scale and with multiple commercialized products.
  • Junshi Biosciences: Leading Chinese innovation-driven biopharmaceutical company developing first-in-class biologics and small molecules across oncology, autoimmune, and metabolic disease; comparable as a Chinese clinical-stage-to-commercial biotech pursuing innovative targets in overlapping disease areas.
  • Innovent Biologics: Larger Chinese biopharmaceutical company developing innovative medicines across oncology, autoimmune, and metabolic disease with multiple approved and clinical-stage assets; comparable in therapeutic-area overlap (autoimmune, metabolic) but at significantly more advanced commercialization stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ennovabio social profiles

Digital presence

Ennovabio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ennovabio leadership team

Management profile

Number of profiles

Profiles6 records

Ennovabio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ennovabio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ennovabio

What does Ennovabio do?

Ennovabio is a clinical-stage biopharmaceutical company that discovers and develops first-in-class therapeutics for autoimmune diseases, diabetic complications, cancer, and metabolic liver diseases. The company uses its proprietary eSTEM Systems Biology Platform, which integrates systems biology with machine learning and deep learning, to identify and prioritize novel drug targets. Its pipeline comprises 6 distinct projects spanning preclinical and clinical development, with internal capabilities covering target assessment, medicinal chemistry, pharmacology, CMC, DMPK, and clinical development.

Is Ennovabio a public or private company?

Ennovabio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ennovabio founded?

Ennovabio was founded in 2018. It employs 1 to 10 people.

Where is Ennovabio based?

Ennovabio is headquartered in Shanghai, China, in the Asia region.

How does Ennovabio make money?

One revenue line is on record: drug Development and Commercialization.

Who are Ennovabio's main competitors?

Direct peers on record are XtalPi, Abbisko Therapeutics, Rona Therapeutics (Darui Biopharma) and Elpiscience Biopharmaceuticals. Emerging players are Insitro, Recursion Pharmaceuticals and Schrödinger. Broad incumbents are BeiGene, Junshi Biosciences and Innovent Biologics.

Does Ennovabio have an API?

No public API is recorded for Ennovabio.

What industry is Ennovabio in?

Ennovabio's product category is Drug Discovery & Development. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales